Fig. 2
FTO is the key factor leading to distinct m6A levels among different growth hormone-secreting pituitary neuroendocrine tumor subtypes. a. Boxplot of m6A regulatory genes expression between DGGH and SGGH. b-c. Boxplot of quantitative PCR analysis of FTO (b) and RBM15 (c) level in a cohort of 69 DGGH and SGGH samples. d. Violin plot of FTO expression in DGGH and SGGH cells in Huashan scRNA-seq cohorts. e. Boxplot showing FTO expression levels in DGGH and SGGH based on dataset GSE214226. f-g. Immunohistochemical staining for FTO in DGGH and SGGH tissue samples. h. Boxplot of FTO expression between non-invasive and invasive GH adenomas. i-k. Verification of FTO knockdown and overexpression in GH3 cells and primary tumor cells in mRNA level through qPCR assays. l. Western blot assays demonstrating the efficacy of FTO knockdown and overexpression in GH3 cells and primary tumor cells. m-n. Bar plots representing global m6A modification levels following FTO manipulation in GH3 cells (m) and primary tumor cells (n). Each experiment was replicated independently at least three times